Center for Advanced Imaging Innovation and Research (CAI2R)

先进成像创新与研究中心 (CAI2R)

• 批准号: 10167922
• 负责人: Daniel K Sodickson
• 金额: $ 77.29万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-20 至 2022-07-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10167922
• 关键词: 2019-nCoV; Accidents; Antibodies; Appearance; Bedside Testings; Biomedical Technology; Blood specimen; COVID-19; COVID-19 pandemic; Chemical Engineering; Chemicals; Clinical; Collaborations; Computer software; Coronavirus spike protein; Country; Data; Data Set; Detection; Development; Devices; Diagnosis; Diagnostic tests; Disease; Electronics; Engineering; Enzyme-Linked Immunosorbent Assay; Evaluation; Eye; Future; Goals; Gold; Health; Home environment; Human; Hydrogen Bonding; Image; Imaging technology; Immune response; Immunity; Immunologic Markers; Infection; Inflammatory; Intelligence; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Membrane Proteins; Methods; Mission; Modeling; Molecular; Molecular Structure; Monitor; Musculoskeletal Diseases; National Institute of Biomedical Imaging and Bioengineering; Nose; Pathology; Patients; Performance; Polymerase Chain Reaction; Positron-Emission Tomography; Printing; Process; Proteins; Protocols documentation; Research; Saliva; Sampling; Scanning; Sensitivity and Specificity; Severities; Shapes; Signal Transduction; Specificity; Sulfhydryl Compounds; Surface; Surface Properties; Swab; Technology; Testing; Time; Transistors; Translating; Validation; Viral; Viral Proteins; Virus; Virus Diseases; Work; base; biobank; bioimaging; biophysical model; blind; clinical care; clinical practice; cohort; commercialization; covalent bond; cytokine; data streams; design; diagnostic accuracy; electrical property; experience; flexibility; imprint; improved; innovation; interest; member; nervous system disorder; novel imaging technique; novel imaging technology; parent grant; point of care; prospective; prototype; reconstruction; response; scale up; sensor; solid state electronics; technology development; technology research and development; tool; virology; voltage; 2019-nCoV; Accidents; Antibodies; Appearance; Bedside Testings; Biomedical Technology; Blood specimen; COVID-19; COVID-19 pandemic; Chemical Engineering; Chemicals; Clinical; Collaborations; Computer software; Coronavirus spike protein; Country; Data; Data Set; Detection; Development; Devices; Diagnosis; Diagnostic tests; Disease; Electronics; Engineering; Enzyme-Linked Immunosorbent Assay; Evaluation; Eye; Future; Goals; Gold; Health; Home environment; Human; Hydrogen Bonding; Image; Imaging technology; Immune response; Immunity; Immunologic Markers; Infection; Inflammatory; Intelligence; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Membrane Proteins; Methods; Mission; Modeling; Molecular; Molecular Structure; Monitor; Musculoskeletal Diseases; National Institute of Biomedical Imaging and Bioengineering; Nose; Pathology; Patients; Performance; Polymerase Chain Reaction; Positron-Emission Tomography; Printing; Process; Proteins; Protocols documentation; Research; Saliva; Sampling; Scanning; Sensitivity and Specificity; Severities; Shapes; Signal Transduction; Specificity; Sulfhydryl Compounds; Surface; Surface Properties; Swab; Technology; Testing; Time; Transistors; Translating; Validation; Viral; Viral Proteins; Virus; Virus Diseases; Work; base; biobank; bioimaging; biophysical model; blind; clinical care; clinical practice; cohort; commercialization; covalent bond; cytokine; data streams; design; diagnostic accuracy; electrical property; experience; flexibility; imprint; improved; innovation; interest; member; nervous system disorder; novel imaging technique; novel imaging technology; parent grant; point of care; prospective; prototype; reconstruction; response; scale up; sensor; solid state electronics; technology development; technology research and development; tool; virology; voltage

PROJECT SUMMARY Competitive Revision to P41 EB017183 The Center for Advanced Imaging Innovation and Research (CAI2R) pursues a mission of bringing people together to create new ways of seeing. The work of our Center has been focused on creating new paradigms for the acquisition, reconstruction, and interpretation of biomedical images, and on implementing new collaboration models in order to translate these developments rapidly into clinical practice. In the proposed Competitive Revision, we will apply our experience in working with biomedical images and other signals to a new collaboration, aimed at the urgent need for COVID-19 testing. Parent Grant Summary The world of biomedical imaging is changing, and CAI2R has been at the forefront of that change. Tasks that were once the sole domain of meticulously-engineered imaging hardware are now beginning to be accomplished in software, increasingly informed by diverse arrays of inexpensive auxiliary sensors. Information once pursued through the laborious acquisition of carefully separated image datasets is now being derived from newly integrated, and richly quantitative, data streams. In keeping with these themes, our Center will be organized around the following four Technology Research and Development (TR&D) projects going forward: 1. Reimagining the Future of Scanning: Intelligent image acquisition, reconstruction, and analysis. 2. Unshackling the Scanners of the Future: Flexible, self-correcting, multisensor machines. 3. Enriching the Data Stream: MRI and PET in concert. 4. Revealing Microstructure: Biophysical modeling and validation for discovery and clinical care. Competitive Revision Summary With the appearance of COVID-19, the world changed suddenly. The need for definitive but also broadly available COVID-19 testing is clear, and is identified as a top priority in the Notice of Special Interest (NOT-EB- 20-008) to which this proposal responds. In this project, we will partner with colleagues in chemical engineering and virology to develop, evaluate, and deploy a new electrochemical device for multifaceted point- of-care or home-based COVID-19 testing. The device will use molecular surface imprinting to create a gold surface sensitive to SARS-CoV-2 spike proteins and other analytes of interest. Sensitive solid-state electronics will then detect the presence of these analytes in patient samples, ultimately allowing rapid and simultaneous assessment of COVID-19 infection, immunity and severity. Specific Aims of the Competitive Revision are as follows: 1. Prototype. We will test whether a COVID-19 signal may already be obtained using our best current imprinting methods and electronic detection circuitry. 2. Characterize. We will use biobanked patient samples to establish sensitivity, specificity, and limits of detection (LOD) of our initial prototype for COVID-19, as opposed to other common viruses. 3. Optimize and iterate. Informed by Aims 1 and 2, we will develop optimized electronics, surface imprinting protocols, and measurement strategies to improve sensitivity and specificity. 4. Evaluate and distribute. We will test designs with promising performance prospectively in a cohort of subjects presenting for testing at NYU, and will compare results with standard RT-PCR COVID-19 testing, with an eye towards FDA approval, commercialization, and broader distribution.

项目摘要 对P41 EB017183的竞争性修订 高级成像创新与研究中心（CAI2R）追求带人的使命 共同创建新的观察方式。我们中心的工作一直致力于创建新的范式 为了获得，重建和解释生物医学图像，并实施新的 为了将这些发展迅速转化为临床实践，协作模型。 在拟议的竞争性修订中，我们将运用我们在使用生物医学图像和 旨在迫切需要进行COVID-19测试的新合作的其他信号。 家长赠款摘要 生物医学成像的世界正在发生变化，CAI2R一直处于这种变化的最前沿。任务 曾经是精心设计成像硬件的唯一领域 在软件上完成，越来越多地由各种廉价的辅助传感器阵列得知。信息 一旦通过艰苦的仔细分离图像数据集进行追求，现在就会得出 来自新集成且丰富的数据流。为了与这些主题保持一致，我们的中心将是 围绕以下四个技术研发（TR＆D）项目组织： 1。重新想象扫描的未来：智能图像获取，重建和分析。 2。解开未来的扫描仪：灵活，自我校正的多传感器机器。 3。丰富数据流：MRI和PET音乐会。 4。揭示微观结构：发现和临床护理的生物物理建模和验证。 竞争性修订摘要 随着Covid-19的出现，世界突然改变了。需要确定的，但也广泛 可用的COVID-19测试很明确，并且被确定为特殊关注通知的首要任务（NOT-EB- 20-008）该提案对此做出回应。在这个项目中，我们将与化学同事合作 工程和病毒学，以开发，评估和部署一种新的电化学设备，用于多方面 由护理或家庭的Covid-19测试。该设备将使用分子表面印记来创建金 表面对SARS-COV-2尖峰蛋白和其他感兴趣的分析物敏感。敏感的固态 然后，电子设备将检测到患者样品中这些分析物的存在，最终允许快速和 同时评估COVID-19的感染，免疫力和严重性。竞争的具体目标 修订如下： 1。原型。我们将测试是否使用我们的最佳电流可以获得COVID-19信号 印迹方法和电子检测电路。 2。特征。我们将使用生物循环的患者样本来建立灵敏度，特异性和限制 与其他常见病毒相反，我们对Covid-19的初始原型检测（LOD）。 3。优化和迭代。由AIM 1和2告知，我们将开发优化的电子设备，表面印记 协议以及提高灵敏度和特异性的测量策略。 4。评估和分发。我们将在一系列的同类中前景地测试具有前瞻性表现的设计 在纽约大学进行测试的受试者，并将结果与​​标准RT-PCR COVID-19测试进行比较， 着眼于FDA批准，商业化和更广泛的分布。